Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1GSK3AGSK3BHRH1HRH2HTR7IDH1IDH2IMPA1IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL9120773 | 1.00 | CA4 (0.73) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL18263181 | 1.00 | CA4 (0.73) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL29276644 | 0.98 | CA4 (0.70) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL3408933 | 0.98 | CA4 (0.70) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL8522371 | 0.98 | CA4 (0.70) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL2908842 | 0.98 | CA4 (0.70) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL5471630 | 0.98 | CA4 (0.76) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL1684057 | 0.95 | CA4 (0.73) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL9319655 | 0.95 | CA4 (0.73) | CA4ALDH1A1HMGCRCHRM1TBXA2R | |
| Citric Acid SCHEMBL21569387 | 0.95 | CA4 (0.73) | CA4ALDH1A1HMGCRCHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4284329-A1 | METHOD FOR DYEING KERATINOUS MATERIAL, COMPRISING THE USE OF AN ORGANOSILICON COMPOUND, A DYEING COMPOUND, A SEALING REAGENT AND A POST-TREATMENT AGENT | Henkel AG & Co. KGaA (DE) | 2023-12-06 | — | — | EP | claimed |
| EP-4228609-A1 | DIRECTLY ADMINISTERED GRANULAR COMPOSITION HAVING A COMBINATION OF DELAYED-RELEASE AND RAPID-RELEASE MAGNESIUM, AND PROCESSES FOR THE PRODUCTION THEREOF | HERMES PHARMA GmbH (DE) | 2023-08-23 | — | — | EP | claimed |
| WO-2023057451-A1 | DIRECTLY ADMINISTERED GRANULAR COMPOSITION HAVING A COMBINATION OF DELAYED-RELEASE AND RAPID-RELEASE MAGNESIUM, AND PROCESSES FOR THE PRODUCTION THEREOF | HERMES PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | claimed |
| WO-2022161663-A1 | METHOD FOR DYEING KERATINOUS MATERIAL, COMPRISING THE USE OF AN ORGANOSILICON COMPOUND, A DYEING COMPOUND, A SEALING REAGENT AND A POST-TREATMENT AGENT | HENKEL AG & CO. KGAA (DE) | 2022-08-04 | — | — | WO | claimed |
| CN-110563994-B | Supercritical foaming nucleating agent and preparation method thereof | 浙江杰上杰新材料有限公司 | 2022-05-24 | — | — | CN | claimed |
| EP-3737246-A1 | FOOD SUPPLEMENT, USES THEREOF, METHOD FOR FOOD SUPPLEMENTATION, AND ORAL SPRAY | URSAPHARM Arzneimittel GmbH (DE) | 2020-11-18 | — | — | EP | claimed |
| CN-111836553-A | Food supplement, use thereof, food supplement method and oral spray | 乌尔萨法姆药物有限责任公司 | 2020-10-27 | — | — | CN | claimed |
| CN-110563994-A | Supercritical foaming nucleating agent and preparation method thereof | 浙江杰上杰新材料有限公司 | 2019-12-13 | — | — | CN | claimed |
| US-20190282475-A1 | High-Performance Hair Treatment Agents With A Proteolipid And A Magnesium Salt | HENKEL AG & CO. KGAA (DE) | 2019-09-19 | — | — | US | claimed |
| CN-110002991-A | A kind of production method for mending magnesium raw material magnesium acid citrate | 宁乡新阳化工有限公司 | 2019-07-12 | — | — | CN | claimed |
| US-20170056305-A1 | HIGH-PERFORMANCE HAIR TREATMENT AGENTS WITH A PROTEOLIPID AND A MAGNESIUM SALT | HENKEL AG & CO. KGAA (DE) | 2017-03-02 | — | — | US | claimed |
| US-20170056311-A1 | HIGH-PERFORMANCE HAIR TREATMENT AGENT COMPIRISING AN OLIGOPEPTIDE AND A MAGNESIUM SALT | HENKEL AG & CO. KGAA (DE) | 2017-03-02 | — | — | US | claimed |
| US-20040057947-A1 | Drug combinations based on magnesium salts and fibrinolytics | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-25 | — | — | US | claimed |
| EP-0634109-B1 | Solid composition for a mineral drink | SCHWILLE PAUL OTTO PROF DR DR (DE) | 2000-09-20 | — | — | EP | claimed |
| EP-0530220-B1 | PHARMACEUTICAL COMPOSITION | S & V ENGINEERING KFT (HU) | 1997-09-03 | — | — | EP | claimed |
| EP-4746710-A1 | DIALKALI OR ALKALINE-EARTH METAL(II) CITRATE AS AN ECO-FRIENDLY AND EFFECTIVE BIOCIDE, PROCESS AND USE THEREOF | Biorem Engineering SA (CH) | 2026-05-27 | — | — | EP | disclosed |
| CN-121248400-A | Preparation method of magnesium hydrogen citrate | 日照金禾博源生化有限公司 | 2026-01-02 | — | — | CN | disclosed |
| EP-0530220-A1 | PHARMACEUTICAL COMPOSITION. | EGAL VEGYIPARI KOEZOES VALLALA (HU) | 1993-03-10 | — | — | EP | disclosed |
| WO-1991016909-A1 | PHARMACEUTICAL COMPOSITION | S+V ENGINEERING KFT, HUNGARY (HU) | 1991-11-14 | — | — | WO | disclosed |
| US-4183362-A | Decreasing the burn rate of smoking tobaccos | LIGGETT GROUP INC. (US) | 1980-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056305-A1 | HIGH-PERFORMANCE HAIR TREATMENT AGENTS WITH A PROTEOLIPID AND A MAGNESIUM SALT | SRRM2, PLP2, KRT18 | CA4 1284/4885ALDH1A1 4855/4885HMGCR 721/4885 |
| US-20170056311-A1 | HIGH-PERFORMANCE HAIR TREATMENT AGENT COMPIRISING AN OLIGOPEPTIDE AND A MAGNESIUM SALT | SLC7A1, OAT, SLC26A4 | CA4 147/4885ALDH1A1 4536/4885HMGCR 1429/4885 |
| US-20190282475-A1 | High-Performance Hair Treatment Agents With A Proteolipid And A Magnesium Salt | SRRM2, PLP2, KRT18 | CA4 1284/4885ALDH1A1 4855/4885HMGCR 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.